Treating Inadequately Controlled Asthma: Exploring the Potential of Phenotype-Targeted Therapy

This symposium took place on 28th September 2015, as part of the European Respiratory Society International Congress 2015 in Amsterdam, Netherlands

Chairperson: Mario Castro1
Speakers: Ratko Djukanovic,2 Michael Wechsler3

1. Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
2. Southampton NIHR Respiratory Biomedical Research Unit, Southampton, UK
3. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, USA

Disclosure: Mario Castro has received research support from NIH, ALA, CDC, Amgen, Boston Scientific, Boehringer Ingelheim, Cephalon, Genentech, GSK, Invion, Johnson & Johnson, Kalobios, MedImmune, NextBio, Novartis, Sanofi Aventis, and Vectura. He is on the lecture bureau for Boehringer Ingelheim, Boston Scientific, Genentech, GSK, and Teva. He has acted as consultant for Boston Scientific, Galera, Genentech, GSK (DSMC), Holaira, MEDA, and Neostem. He holds stock in Sparo Labs. Ratko Djukanovic has acted as consultant for Teva, Novartis, Merck, Boehringer Ingelheim, and Synairgen. Michael Wechsler has provided consulting services to the following companies: Teva, GSK, Genentech, Boston Scientific, Novartis, Merck, AstraZeneca, and Boehringer Ingelheim.
Acknowledgements: Writing assistance was provided by Dr Tabasum Mughal, ApotheCom.
Support: The publication of this article was funded by Teva Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily of Teva Pharmaceuticals.
Citation: EMJ Respir. 2015;3(2):42-48.

Meeting Summary

Asthma is inadequately treated with the current standard of care. This session aimed to explore the potential of a phenotype-targeted approach to asthma management, which would allow a more tailored approach to treatment and result in better clinical outcomes for difficult-to-treat patients. Evidence was presented indicating that eosinophils play an important role in the pathogenesis of asthma. The importance of anti-interleukin (IL)-5 therapies, with the focus on therapies currently in development and their potential clinical benefit for the eosinophilic asthma phenotype, was also explored.

Download (PDF, 169KB)

Comments are closed.